Evidence map›Paper›PMID 34404435›Full record

ArticleJournal of translational medicine2021

Fibroblast growth factor 11 (FGF11) promotes non-small cell lung cancer (NSCLC) progression by regulating hypoxia signaling pathway.

Xiaowei Wu, Minjie Li, Ying Li, Yu Deng, Shun Ke, Fan Li, Yujin Wang, Shuchang Zhou

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Xiaowei Wu *Department of Thoracic Surgery, Ersity of Science and Technology, Tongji Hospital, Tongji Medical Collage of Huazhong Univ, 430030, Wuhan, Hubei, China.
Minjie Li *Department of Thoracic Surgery, Zhongshan Hospital, Xiamen University, Xiamen, 361004, Fujian, China.
Ying Li *Department of Nuclear Medicine, Dongzhimen Hospital of Beijing University of Chinese Medicine, Beijing, China.
Yu DengDepartment of Thoracic Surgery, Ersity of Science and Technology, Tongji Hospital, Tongji Medical Collage of Huazhong Univ, 430030, Wuhan, Hubei, China.
Shun KeDepartment of Emergency Medicine, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, 430030, Wuhan, Hubei, China.
Fan LiDepartment of Thoracic Surgery, Ersity of Science and Technology, Tongji Hospital, Tongji Medical Collage of Huazhong Univ, 430030, Wuhan, Hubei, China.
Yujin WangDepartment of Radiology, Tongji Hospital, Tongji Medical Collage of Huazhong University of Science and Technology, 430030, Wuhan, Hubei, China.
Shuchang ZhouDepartment of Radiology, Tongji Hospital, Tongji Medical Collage of Huazhong University of Science and Technology, 430030, Wuhan, Hubei, China. ferhk336@163.com.ORCID 0000-0002-9308-5706
Tongji Hospital · CNDongzhimen Hospital Affiliated to Beijing University of Chinese Medicine · CNZhongshan Hospital of Xiamen University · CN

Funding

Natural Science Foundation of Hubei Province 2020CFB740
6 · The paper itself

Abstract

backgroundAccumulating evidence highlights the critical roles of fibroblast growth factors (FGFs) in regulating the progression of multiple human cancers, including non-small cell lung cancer (NSCLC). In this study, we investigated the role of FGF11 in the progression of NSCLC.

methodsPreviously published transcriptomic data (GSE75037 and GSE81089) were used to compare FGF11 expression level between NSCLC tumor tissues and adjacent normal tissues. 100 cases of NSCLC tumor tissues and 30 cases of matched adjacent normal tissues were used to validate FGF11 expression at mRNA and protein level by qPCR and immunohistochemistry. Bioinformatics analysis and dual luciferase reporter analysis were performed to confirm the regulatory effect of miR-525-5p on FGF11 expression. CCK-8 assay and transwell migration assay were employed to examine cellular proliferation, migration and invasion. Gene set enrichment analysis (GSEA) was performed to identify the signaling pathway associated with FGF11 expression. Finally, the functional role of FGF11 in NSCLC tumor growth was evaluated by in vivo study.

resultsFGF11 was upregulated in NSCLC tumor tissues and tumor cell lines. High FGF11 expression was associated with a poor prognosis in NSCLC patients. In vitro loss- and gain-of function experiments demonstrated that FGF11 knockdown inhibited, whereas FGF11 overexpression promoted the proliferation, migration and invasion of NSCLC cells. Dual luciferase reporter assay confirmed that FGF11 was downregulated by miR-525-5p, and the effect of FGF11 on cell proliferation, migration and invasion could be interfered by miR-525-5p. GSEA analysis further revealed that FGF11 expression was enriched with genes in hypoxia signaling pathway and the oncogenic function of FGF11 could be suppressed by knocking down HIF-1α in NSCLC cells. Moreover, FGF11 knockdown suppressed NSCLC tumor growth whereas FGF11 overexpression promoted tumor growth in vivo.

conclusionsOur study showed that FGF11 functions as an oncogene in tumor NSCLC progression. miR-525-5p seems to negatively regulate FGF11 and the oncogenic role of FGF11 is dependent on the upregulation of HIF-1α. Our study suggests that targeting FGF11 and HIF-1α may serve as novel strategies for the treatment of NSCLC.

Indexed as

Carcinoma, Non-Small-Cell LungFibroblast Growth FactorsLung NeoplasmsMicroRNAsCell ProliferationHumansHypoxiaSignal TransductionFGF11 protein, humanFibroblast Growth FactorsMicroRNAsCell proliferationFGF11HIF-1αHypoxiaNSCLC

Identifiers

PMID34404435
PMCPMC8369785
OpenAlexW3154357781

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.